Scalper1 News
Canadian specialty-drug giant Valeant Pharmaceuticals International (VRX) beat Q1 estimates and raised its guidance, but it also announced the departure of the CFO who’s overseen finances during its period of greatest growth. Valeant early Wednesday posted revenue of $2.19 billion, up 16% from the year-earlier quarter and about $40 million above analysts’ consensus, according to Thomson Reuters. Cash earnings per share rose 10% to $2.36, beating Scalper1 News
Scalper1 News